Member Info for TheOxfordDon

Remaining very positive and optimistic. Two fronts to give us cheers;

1 Product development and take up

2 External interest from several sources

HNY -The "We"is inclusive and certainly Management, staff and shareholders all included.

Whilst the last 3 months have seen choppy waters and treacle like conditions, calmer conditions lay ahead and we are very confident that 2026 will indeed see our previously posted 5p for this share. Papers and projections are very positive and within its category it should out-perform mean levels. We continue to recommend as a strong buying opportunity.

Just passing through this forum again, and felt it worth while just to reiterate our strong buy recommendation. We remain of the opinion that a 2026 high of 5.0p is well within navigable waters with further upward movement a distinct possibility .

There is a lot of "stuff" and "noise" around prostate cancer within the UK at present and this is being replicated throughout Europe and the USA. The OBD test was never going to be the base line "own brand" test but as positive test results rise exponentially, ( as they will) , bespoke testing will come to the fore,and EpiSwithch is positioned really well to take advantage of this.

We can only hope that the management of the company have identified these opportunities and are making representations in the right quarters.

5.0p is well within reach. Hold what you have and extend holdings as appropriate

That was all relatively straightforward.

Opinion upgraded to Strong Buy.

We can take comfort in the Board strategy. Credit to Iain Ross for his vision and leadership.

On the basis of pre returned third party and nominee ballots

This is shaping up as a bigger percentage YES vote than anticipated. Both this position and that of Nanopore at the other end of the Science Park looking well under bought. I'm excited !

Contrary to that posting I most certainly am not a member of staff nor am associated in any capacity with OBD. Since my last posting further underlying positive developments and we for one have faith in the current management team to see this through. Ironically had the placing of shares been at say 0.43 the shares would be trading at that such is the confidence behind OBD. It is looking like 80% + of those that vote will be casting their chips on YES

Straight bat indeed. The news of the NHS AI trial for prostate cancer is a big plus for this position as that trial will only ever detect possibilities and the EpiSwitch could play a very big part in confirmation pre any treatment.

I'm hearing many positive noises regarding desires to take up the new placement funding and this is to be welcomed and applauded. Remains a weak buy purely because we have all been at this long enough to know curved balls can get thrown in, but once the placement is completed to our satisfaction then we would advise a much more robust approach to buying and our upside tick remains at 5p with a progressive overview.

Sorry typo, that should read 5.0p not 0.5.

Just to address a comment to my last post. I consider this a buy. I consider that buy as weak at the moment as outcome of meeting not yet known nor the year end finals. My 0.5p is measured and considered and % wise it may represent a four figure gain but its fraught with possibly a rollercoaster ride until the headwinds ease.

The daily book for the traders will always have an unrepresented effect on the share price, but even those daily sharks will begin to stay on board as underlying trends and financials improve.

I'm onboard for the vote and I would urge fellow shareholders ( who have a belief in the company and the lifechanging value of its products and services ) to follow me into the positive lobby.

A pretty honest update from Iain Ross which gave a comprehensive update on the financials and future. I was initially very alarmed by the very small number of PSE Test kits only being 215 (Sept 2025) up from 100 (Sept 2024). However the upside for increasing sales and therefore revenue is very considerable, and with the appropriate licencing partnerships in the USA it is not unreasoned to think that a significant uptick in revenues is more probable than possible.

The product specifications and patents of OBD are scientific leading and innovative and perhaps in the past OBD have not been exemplars in marketing (selling) the product(s) but we can take comfort in the leadership of Iain Ross.

I sincerely hope the fund raising placement goes well and I'm sure it will. The share price wont move much until after Extraordinary General meeting perhaps with a small uptick to trade in the .035-0.4 range, but I expect measurable progress over the next 6 months and I've set an attainment target of 5.0p by July 2026 .

An awful lot can happen with this stock and you only have to read the full script from Iain Ross. One could argue its been a bit like "whacky races" with a few golden nuggets , but I am comfortable with the way forward a the stock I still rank as "buy" albeit moderated to a weak one as like whacky races there is a good few obstacles ahead.